Acute and subchronic toxicity and genotoxicity of SE5-OH, an equol-rich product produced by Lactococcus garvieae.

The consumption of soy-based products is associated with a number of health benefits and much of these benefits are proposed to be due to the soy isoflavones daidzein, genistein, glycitein, their glycosides, and equol, an isoflavone naturally produced from daidzein. Equol is a naturally bacterially-derived metabolite of daidzein and is produced by bacteria in the gut of those humans capable of hosting the particular organism. To allow all humans to enjoy the health benefits of equol, a new functional food ingredient has been developed that relies on bacterial conversion of daidzein to equol under strictly controlled conditions. This new food substance, termed SE5-OH, has been studied extensively for its acute and subchronic toxicity in Sprague-Dawley rats, as well as for its potential genotoxicity. The oral LD(50) is >4,000 mg/kg. In a 91-day, subchronic study, the no-observed-adverse-effect-level (NOAEL) was 2,000 mg/kg/day, the highest dose tested. SE5-OH was negative in Salmonella typhimurium tester strains TA98, TA100, TA1535 and TA1537 and in Escherichia coli tester strain WP2uvrA with and without metabolic activation. SE5-OH was negative for chromosome aberrations in Chinese hamster lung cells up to 3,000 microg/ml with and without metabolic activation and did not induce increases in micronucleated polychromatic erythrocytes taken from Sprague-Dawley rats administered (via gavage) up to 4,000 mg/kg SE5-OH twice daily for two consecutive days.

Regional mutagenicity of heterocyclic amines in the intestine: mutation analysis of the cII gene in lambda/lacZ transgenic mice.

Transgenic mouse assays have revealed that the mouse intestine, despite its resistance to carcinogenesis, is sensitive to the mutagenicity of some heterocyclic amines (HCAs). Little is known, however, about the level and localization of that sensitivity. We assessed the mutagenicity of four orally administered (20 mg/kg per day for 5 days) HCAs-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) hydrochloride, 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ), and 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2) acetate-in the intestine of male MutaMice. Two weeks after the last administration, we isolated epithelium from the small intestine, cecum, and colon and analyzed lacZ and cII transgene mutations. PhIP increased the lacZ mutant frequency (MF) in all the samples, and in the small intestine, cII and lacZ MFs were comparable. In the cII gene, G:C to T:A and G:C to C:G transversions were characteristic PhIP-induced mutations (which has also been reported for the rat colon, where PhIP is carcinogenic). In the small intestine, PhIP increased the cII MF to four-fold that of the control, but IQ, MeIQ, and Trp-P-2 did not have a significant mutagenic effect. In the cecum, cII MFs induced by IQ and MeIQ were 1.9 and 2.7 times those in the control, respectively. The MF induced by MeIQ in the colon was 3.1 times the control value. Mutagenic potency was in the order PhIP>MeIQ>IQ; Trp-P-2 did not significantly increase the MF in any tissue. The cecum was the most susceptible organ to HCA mutagenicity.